Han Zeng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10081216/publications.pdf

Version: 2024-02-01

28	723	1040056	752698
papers	citations	9	20
		h-index	g-index

28	28	28	629
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Poor clinical outcomes and immunoevasive contexture in SIRPÎ±+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 109.e11-109.e20.	1.6	3
2	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1497-1506.	4.2	20
3	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e15-166.e25.	1.6	6
4	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology, 2022, , 1.	1.5	4
5	ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology, 2022, 29, 2504-2504.	1.5	0
6	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 2117-2126.	4.2	1
7	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. British Journal of Cancer, 2022, 126, 1310-1317.	6.4	7
8	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. British Journal of Cancer, 2022, 126, 1581-1588.	6.4	16
9	Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
10	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
11	Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
12	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	2
13	Intratumoral IL22â€producing cells define immunoevasive subtype muscleâ€invasive bladder cancer with poor prognosis and superior nivolumab responses. International Journal of Cancer, 2020, 146, 542-552.	5.1	22
14	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 293-304.	1.6	10
15	Tumor-infiltrating TNFRSF9 ⁺ CD8 ⁺ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. OncoImmunology, 2020, 9, 1838141.	4.6	23
16	Poor clinical outcomes and immunoevasive contexture in interleukinâ€9 abundant muscleâ€invasive bladder cancer. International Journal of Cancer, 2020, 147, 3539-3549.	5.1	8
17	Intratumoral CCR5 ⁺ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. OncoImmunology, 2020, 9, 1802176.	4.6	4
18	Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 ⁺ CD8 ⁺ T cell abundance. OncoImmunology, 2020, 9, 1810489.	4.6	7

#	Article	IF	Citations
19	Intratumoral TIGIT⁺ CD8⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
20	CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1855-1867.	4.2	35
21	CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. , 2020, 8, e000228.		15
22	Stromal LAG-3⁺cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. , 2020, 8, e000651.		29
23	Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 1707-1719.	0.9	61
24	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
25	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin ⁺ cell abundance. OncoImmunology, 2020, 9, 1747333.	4.6	13
26	Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 1565-1576.	4.2	72
27	Tumor-infiltrating IL-17A ⁺ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. OncoImmunology, 2020, 9, 1747332.	4.6	6
28	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. European Urology, 2019, 75, 752-763.	1.9	123